TABLE 3B.
Effects of adenosinergic drugs in memory deficiency models: BIIP 20 ((S)-(–)-8-(3-oxocyclopentyl)-1,3-dipropyl-7H-purine-2,6-dione), FR 194921 (2-(1-methyl-4-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-3(2H)-pyridazinone), KF 15372 (8-Dicyclopropylmethyl- 1,3-dipropylxanthine), KW 6002 ((E)-1,3-diethyl-8-(3, 4-dimethoxystyryl)-7-methyl-3,7-dihydro-1H-purine-2,6-dione), ZM 241385 (4-(2-[7-amino-2-(2-furyl{1,2,4}-triazolo{2,3-a{1,3,5}triazin-5-ylaminoethyl) phenol); the full names of the other drugs are provided in Table 1. ↓ / ↑: potentiates/ attenuates the memory impairment; ↔ no effect.
| • Adenosinergic drugs on memory functions in memory impairment models | |||||
|---|---|---|---|---|---|
| Memory impairment models | Behavioural models | Adenosinergic action | Drug | Effects on amnesic effect | References |
| NMDAR-antagonist | Inhibitory avoidance | A1R/A2R antagonist | Caffeine | ↔ | Dall'Igna et al., 2003 |
| #x2191; | de Oliveira et al., 2005 | ||||
| Delayed alternation | A1R agonist | CPA | ↔ | Fraser et al., 1997 | |
| A2AR agonist | DPMA | #x2191; | |||
| A1R antagonist | CPX | #x2191; | |||
| A2AR antagonist | KW 6002 | ↔ | Cunha et al., 2008 | ||
| SCH 58261 | ↔ | ||||
| A1R/A2R antagonist | Caffeine | #x2191; | de Oliveira et al., 2005 | ||
| ↔ | Dall'Igna et al., 2003 | ||||
| Spontaneously hypertensive rats | Passive avoidance | A1R antagonist | BIIP 20 | #x2191; | Pitsikas and Borsini, 1997 |
| Object recognition | A1R antagonist | DPCPX | #x2191; | Pires et al. 2009 | |
| A2AR antagonist | 7M 241385 | #x2191; | |||
| A1R/A2R antagonist | Caffeine | #x2191; | |||
| Social recognition | A1R antagonist | DPCPX | #x2191; | Prediger et al., 2005a | |
| Aging | olfactory discrimination | A1R antagonist | DPCPX | ↔ | Prediger et al., 2005c |
| A2AR antagonist | ZM 241385 | #x2191; | |||
| A1R/A2R antagonist | Caffeine | #x2191; | |||
| Social recognition | A1R/A2R antagonist | Caffeine | ↓ | Prediger et al., 2005b | |
| Scopolamine | Passive avoidance | A1R antagonist | KF 15377 | #x2191; | Suzuki et al., 1993 |
| dicyclopropylmethyl | #x2191; | ||||
| 3-oxocyclopentyl | #x2191; | ||||
| Inhibitory avoidance | A1R antagonist | FR194921 | #x2191; | Maemoto et al., 2004 | |
| A1R/A2R antagonist | Theophylline | #x2191; | Jin at al., 2000 | ||
| Delayed alternation | A2AR agonist | DPMA | ↔ | Fraser et al., 1997 | |
| A2AR antagonist | KW 6002 | ↔ | Cunha et al., 2008 | ||
| SCH 58261 | ↔ | ||||
| A1R antagonist | CPX | ↔ | |||
| β-amyloid peptide | Delayed alternation | A2AR antagonist | KW 6002 | #x2191; | Cunha et al., 2008 |
| SCH 58261 | #x2191; | Cunha et al., 2008 | |||
| Dall'Igna et al., 2007 | |||||
| A1R/A2R antagonist | Caffeine | #x2191; | Dall'Igna et al., 2007 | ||
| Inhibitory avoidance | A2AR antagonist | SCH 58261 | #x2191; | Dall'Igna et al., 2007 | |
| A1R/A2R antagonist | Caffeine | #x2191; | |||
| Spatial & object recognition | A2AR antagonist | SCH 58261 | #x2191; | Canas et al., 2009 | |
| A1R/A2R antagonist | Caffeine | #x2191; | |||
| Reference memory | A1R/A2R antagonist | Caffeine | #x2191; | Arendash et al., 2006 | |
| Working memory | #x2191; | ||||
| Resperine treatment | Social recognition | A2AR antagonist | ZM 241385 | #x2191; | Prediger et al., 2005d |
| A1R/A2R antagonist | Caffeine | #x2191; | |||
| Convulsion in early in life | Spatial recognition | A2AR antagonist | ZM 241385 | #x2191; | Cognato et al., 2010 |
| A1R/A2R antagonist | Caffeine | #x2191; | |||
| Morphine | Passive avoidance | A1R/A2R agonist | NECA | #x2191; | Khavandgar et al., 2002 |
| Pentylenetetrazole | Passive avoidance | A1R/A2R antagonist | Theophylline | #x2191; | Homayoun et al., 2001 |
| Alcohol | Odour recognition | A1R/A2R antagonist | Caffeine | #x2191; | Spinetta et al., 2008 |